XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Discontinued Operations (Details)
$ in Millions
1 Months Ended
Jul. 31, 2022
USD ($)
Royalty Pharma | Disposed of by Sale | TRC | Measurement Input, Discount Rate [Member]  
Theravance Respiratory Company, LLC  
Equity method investment, contingent consideration 7.83
Royalty Pharma | Purchase Agreement to Sell Units in Theravance Respiratory Company, LLC  
Theravance Respiratory Company, LLC  
Percentage of Right to Receive Royalty Transferring 85
Proceeds from sale of units. $ 1,100.0
Consideration Receivable at closing $ 250.0
TRC  
Theravance Respiratory Company, LLC  
Percentage of economic interest 85.00%